Overview

Selinexor is a selective inhibitor of exportin 1 (XPO1) used in multiple myeloma populations that have already been through several prior lines of therapy. The population focus is on refractory disease where standard immunomodulatory and proteasome-based regimens have failed, so a mechanistically distinct agent is needed. The 20 mg tablet from Karyopharm and DAXIONG, supplied in 16-tablet packs, is positioned for later-line use rather than first exposure. Choosing the right refractory population matters because the agent's side-effect profile demands careful supportive care that frailer patients may not tolerate.

How It Works

Selinexor binds the nuclear export protein XPO1 and blocks it from shuttling tumor-suppressor and growth-regulatory proteins out of the nucleus. By trapping these proteins inside the nucleus, it restores apoptotic signaling and disrupts survival pathways that myeloma cells rely on. This nuclear-retention mechanism is unrelated to IMiD or proteasome action, which explains its role after those classes are exhausted. Retaining tumor suppressors such as p53 and FOXO inside the nucleus also restores senescence and stress-response programs lost during myeloma evolution.

Indications

Selinexor is combined with dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least four prior therapies and are triple-class exposed. It is also used in certain diffuse large B-cell lymphoma contexts. Selection weighs prior line count, cytogenetic risk, and performance status. Cytogenetic high-risk features and prior exposure to CAR-T or bispecific agents further define the later-line population that may still benefit.

Dosage & Administration

Dosing is typically twice weekly on specific days, with dose levels adjusted for tolerability and body size. The 16-tablet pack supports a defined run of treatment cycles. Anti-nausea and supportive measures are planned alongside to manage the characteristic gastrointestinal effects and maintain patient adherence.

Storage & Sourcing

Store Selinexor tablets at room temperature below 30°C in the original container, protected from moisture. As an oral targeted agent it ships without cold-chain, easing international supply. Confirm batch, expiry, and serialization on receipt for full traceability. Ambient storage and straightforward oral dosing make outpatient continuation feasible once acute side effects are controlled.

FAQ

Q: Which relapsed or refractory myeloma populations receive Selinexor? A: Adults with four or more prior lines who are refractory to proteasome inhibitors, immunomodulatory drugs, and CD38 antibodies are the core population.

Q: Why is Selinexor paired with dexamethasone in later lines? A: Corticoid support mitigates nausea and fatigue and contributes independent antimyeloma activity in the combination regimen.

Q: What baseline counts guide Selinexor use in frail patients? A: Platelet and neutrophil counts, plus nutritional status, are reviewed before start, because myelosuppression and weight loss require proactive management.